Personalis Inc Stock
Price
Target price
€1.35
€1.35
1.290%
0.018
1.290%
€4.25
01.12.23 / Tradegate
WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Personalis Inc Stock
There is an upward development for Personalis Inc compared to yesterday, with an increase of €0.018 (1.290%).
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Personalis Inc.
Based on the current price of 1.35 € the target price of 4 € shows a potential of 196.96% for Personalis Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Personalis Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Personalis Inc in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Personalis Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Personalis Inc | 1.290% | -4.536% | 26.124% | -50.750% | -23.007% | -94.340% | - |
| Stoke Therapeutics Inc | -1.160% | -2.299% | -10.526% | -50.000% | -59.281% | -91.005% | - |
| Precision BioSciences Inc | -1.800% | -7.735% | -13.472% | -73.845% | -64.513% | -96.047% | - |
| Immuron | 2.190% | 10.000% | 19.108% | -0.532% | -6.500% | -66.903% | - |
Comments
Personalis, Inc. (NASDAQ: PSNL) had its price target lowered by analysts at Needham & Company LLC from $7.00 to $2.30. They now have a "buy" rating on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
News
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a